Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Colon cancer
Trial Type:  Treatment
Treatment/Intervention:  antiangiogenesis therapy
Trial Status:  Active
Trial Phase:  Phase III
Results 1-19 of 19 for your search:
Start Over
Study of Anlotinib in Patients With Metastatic Colorectal Cancer(mCRC)(ALTER0703)
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALTN-07-IIB, NCT02332499
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000549541, USCTU-4351, USCTU-EPOC, EUDRACT-2006-003121-82, ISRCTN22944367, EU-20732, EPOC, NCT00482222
Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 79
Sponsor: Other
Protocol IDs: ICOG-CC01, NCT00497107
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ML22011, NCT01249638
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 70 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000692257, NCCTG-N0949, N0949, NCT01279681
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: CPP-450, 2010-019140-39, NCT01317433
The Role of Surgery of the Primary Tumour With Few or Absent Symptoms in Patients With Synchronous Unresectable Metastases of Colon Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAIRO4, NCT01606098
Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: OBELICS, 2011-004997-27, NCT01718873
Sequential Treatment Strategy for Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRST153.01, 2007-004539-44, NCT01878422
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: STRATEGIC-1 C12- 2, 2013-001928-19, NCT01910610
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SALTO, NCT01918852
Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10040090, NCT01955837
A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: AXEPT, UMIN000012263, NCT01996306
Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1199.52, 2012-000095-42, NCT02149108
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAIRO5, 2013-005435-24, NCT02162563
A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2013-013-00CH1, NCT02314819
Panitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 20 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: Panitumumab-3001, U1111-1164-9167, NCT02394795
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in an Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 20 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: Panitumumab-4004, U1111-1167-3521, NCT02394834
Start Over